Heparin Bridging Protocol for Atrial Fibrillation with Mechanical Valve

Introduction to Bridging Therapy

The American Heart Association recommends bridging therapy with unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH) for patients with atrial fibrillation and a mechanical heart valve when warfarin must be interrupted for procedures, due to the high thromboembolic risk (>10% annually) in this population 1, 2

Patients with mechanical heart valves face a high thromboembolic risk, making bridging non-negotiable regardless of CHA₂DS₂-VASc score, with a risk of >10% annually 1, 2, 3
The mechanical valve itself mandates bridging, which is different from non-valvular AFib where bridging is generally avoided 4

The American College of Cardiology recommends stopping warfarin 5 days before the procedure and starting bridging anticoagulation when INR falls below 2.0, typically 36-48 hours after the last warfarin dose 5, 6
LMWH is preferred over UFH due to its outpatient administration capability, predictable bioavailability, and no monitoring requirements, with a therapeutic dose of twice daily (e.g., enoxaparin 1 mg/kg subcutaneously every 12 hours) 6, 3
The European Society of Cardiology recommends alternative UFH dosing as a continuous IV infusion targeting aPTT 1.5-2.5 times control, though this requires hospitalization 6

The American Heart Association recommends resuming warfarin the evening of the procedure at the usual maintenance dose and resuming bridging anticoagulation 24 hours post-operatively or when adequate hemostasis is secured 1, 5, 3
Bridging should be continued until INR reaches a therapeutic range (2.0-3.0) on two consecutive measurements, not just when INR first reaches 2.0 3

The European Heart Journal recommends monitoring anti-Xa levels if available, targeting 0.5-1.0 U/mL, particularly in patients with renal insufficiency (CrCl <30 mL/min), obesity (>120 kg or BMI >35), or pregnancy, when using LMWH 6
No routine monitoring is needed in standard patients when using LMWH 3

The landmark BRIDGE trial showed that mechanical valve patients were specifically excluded from the trial, highlighting the different approach needed for this population 1, 2, 3
Meta-analyses confirm that in mechanical valve patients, bridging carries a 2.8% major bleeding risk but only 0.9% thromboembolism risk, making the risk-benefit ratio favorable 2

For procedures with very high bleeding risk, consider delaying bridging resumption beyond 24 hours post-operatively until hemostasis is definitively secured, and restart warfarin on schedule but delay heparin restart by 48-72 hours if needed 5
Adjust LMWH doses for CrCl <30 mL/min and monitor anti-Xa levels, and consider UFH instead of LMWH in severe renal impairment (CrCl <15 mL/min) due to unpredictable LMWH clearance 6